Development and application of the direct mycobacterial growth inhibition assay: a systematic review.

ABSTRACT:

Introduction

First described by Wallis et al. in 2001 for the assessment of TB drugs, the direct mycobacterial growth inhibition assay (MGIA) offers a tractable ex vivo tool measuring the combined influences of host immunity, strain virulence and intervention effects. Over the past 13 years, we have led efforts to adapt the direct MGIA for the assessment of TB vaccines including optimisation, harmonisation and validation of BCG vaccine-induced responses as a benchmark, as well as assay transfer to institutes worldwide.

Methods

We have performed a systematic review on the primary published literature describing the development and applications of the direct MGIA from 2001 to June 2023 in accordance with the PRISMA reporting guidelines.

Results

We describe 63 stu

SUBMITTER: Painter H 

PROVIDER: S-EPMC10877019 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature